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ABSTRACT 
In today’s lifestyle woman’s status is expected to reach new horizons both socially and physically 
but some of the physiological things trouble the lady to make her slow down the race, by 
disturbing the normal menstruation, which is the function of Apana vayu. One of such problem is 
‘Kashtartava’ (Dysmenorrhoea) i.e. painful menstruation.  
In Ayurvedic texts, though various conditions are described in which menstruation occurs with 
pain but Kashtartava is not mentioned specifically. It is a symptom of various Yonivyapadas 
specially Udavarta, Vatala, Sannipatika etc. The genital tract of women does not get affected 
without Vata, Hence one should pacify it first and then treat the other Doshas. For Vata dosha basti 
chikitsa is very important. 
Matrabasti is used by someone who emaciated by overwork or too much exercise, too much heavy 
lifting, walking too long of a distance, too much sexual activity or someone with Vata disorders. 
One of the effects of Matrabasti is “Vatarognut”, Hence Matrabasti may be effective on Kashtartava 
(Dysmenorrhoea).  
From above study, it can be concluded that due to Basti chikitsa vitiated Vata dosha gets mitigated 
and hence all the symptoms diminish and it has been observed that Til taila Matra Basti is very 
effective in subjects of Kashtartava (Primary Dysmenorrhoea). 
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INTRODUCTION
The Tridosha i.e. Vata, Pitta and Kapha 
regulates every physiological and psychological 
process in the living organisms(1). Harmonious state 
of the three Doshas creates balance and health; an 
imbalance, which might be an excess (Vriddhi) or 
deficiency (Kshaya), manifests as a sign or symptom 
of disease. 
Apana is one of the five types of Vata Dosha. It 
is located in the Apana, moves in Shroni, Basti, 
Medhra and Uru. It attends to the functions such as 
Nishkramana of Shukra, Artava, Shakrut, Mutra and 
Garbha. One of the functions of Apana vata that is 
Artava nishkraman karma(2). In this study word 
Artava is used for “menstrual Blood” (i.e. Rajstrava). 
In today’s lifestyle woman’s status is expected 
to reach new horizons both socially and physically 
but some of the physiological things trouble the lady 
to make her slow down the race, by disturbing the 
normal menstruation, which is the function of Apana 
vayu. One of such problem is ‘Kashtartava’ 
(Dysmenorrhoea) i.e. painful menstruation.  
In Ayurvedic texts, though various conditions 
are described in which menstruation occurs with 
pain but Kashtartava is not mentioned specifically. It 
is a symptom of various Yonivyapadas specially 
Udavarta, Vatala, Sannipatika etc. The genital tract of 
women does not get affected without vata, Hence one 
should pacify it first and then treat the other 
Doshas(5). 
As in all cases of Kashtartava, Vataprakopa is 
the main cause; the treatment should be directed to 
treat the Vata dosha and eradication of the cause. 
This is the main principle of treatment of 
Kashtartava. 
Matrabasti is one of the types of Basti. It can 
be administered to any individual, at any time. It 
doesn’t cause any Vyapada. It is administered in a 
smallest quantity (i.e. Hraswa matra of snehapana) 
without any Pathya aahar and Vihara.(6) 
Therefore this study was effort to approach 
the effect of Matrabasti in the subjects suffering from 
Kashtartava.  
AIMS AND OBJECTIVES 
To study Kashtartava (Primary 
Dysmenorrhoea) from Ayurveda and Modern point of 
view. 
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MATERIALS AND METHODS 
Conceptual study: Detailed study of Kashtartava 
(Primary Dysmenorrhoea) along with the review of 
drugs chosen for Matra Basti from all available books 
and internet was carried out. 
Clinical Study: Patients attending the OPD and IPD of 
the Y.M. T. Ayurvedic College and Hospital, Kharghar, 
Navi Mumbai, were enrolled for the study. 
Number of Patients  
Total number of patients included in this study was 
30. 
Inclusion criteria 
 Subjects with chief complain of Kashtartava 
(Primary Dysmenorrhoea) with scanty or average 
amount of menstrual fluid. 
 Age group between 15-25 yrs 
 Subjects suffering for more than 2 cycles 
 Regular menses 
Exclusion Criteria 
 Subjects below the age of 15 years and above the 
age of 25 years 
 Subjects with chronic general illness 
 Subjects with Intrauterine contraceptive devices 
 Menorrhagia 
 Any uterine pathology 
o Fibroid 
o Adenomyosis 
o Endometriosis 
 Irregular menses 
Consent 
 An informed written consent was taken from 
all the subjects included in this study. In subjects 
below the age of 18 yrs consent was taken by their 
guardians. 
Methodology 
Plan of study 
 30 subjects were included in the study according 
to inclusion criteria. 
 Each subject was examined thoroughly according 
to Case Record Form (CRF). 
Laboratory Investigations  
a) Haematological 1) Hb – To know the severity 
 2) W.B.C – To rule out infection  
 3) ESR – Rate of infection 
b) Sonography (Pelvis) (for uterine and adenexal 
study, if needed to rule out any pathology or lesion.) 
Drug administration details 
Subjects were treated with Til Taila 
Matrabasti which contains: Til Taila (Koshna) (60 
ml), Saindhav (1 gm) and Shatpushpa churna (2 gms). 
Poorva Karma: Sthanik Abhyang and Sthanik 
Svedana over Kati, Prushta and Nitamba region 
Pradhan karma: Til Taila Matrabasti was 
administered slowly through the rectum in left lateral 
position. 
Pashchat Karma: Sphik Savahan, Subjects were 
allowed to sleep in supin position for 10 min, 
Bastidharan kala of subjects were noted in Case 
Record Form (CRF) on next day. 
Duration of the Treatment - 9 days prior to the 
expected date of each menstrual cycle for 2 
consecutive menstrual cycles.  
Follow up: After every cycle of Matrabasti and one 
month after Completion of treatment follow ups of 
the subjects were taken, Symptom wise clinical 
readings were noted. 
Bastidravya(7) 
 Koshna Til taila (sesame oil) 
 Shatpushpa Churna 
 Saindhav (Rock salt) 
Criteria of Assessment 
 The efficacy of the therapy is assessed on the 
basis of objective criteria. Most of the symptom like 
pain and associated symptoms regarding Kashtartava 
are subjective in nature. Hence scoring system is 
adapted for statistical analysis and to give results on 
objective parameters. Score was given according to 
absence of symptoms (Normal), mild, moderate and 
severe symptoms as follows. 
Assessment of Effect of Therapy 
The effect of the therapy was assessed in 
terms of cured, markedly improved, improved, and 
unchanged and LAMA. 
Following symptoms were assessed- Pain (Primary 
Dysmenorrhoea) - Severity of pain (Multidimensional 
scoring pattern), Duration of pain; Artava Pramana 
(Assessment by number of pads used), Rajstrav 
Avadhi (Duration of menses), Nausea, Vomiting, 
Diarrhoea, Constipation, Faints and Giddiness. 
The details are as follows 
1. Cured: Total relief in symptoms will be 
considered as “Cured”.  
2. Markedly Improved: 50% or more average 
improvement in signs and symptoms will be 
termed as “Markedly improved”.  
3. Improved: Improvement ranging in between 
25% to 50% responded by the subjects in signs 
and symptoms will be taken for “Improved”.  
4. Unchanged: Those subjects presenting less than 
25% improvement in their signs and symptoms 
will be categorized as “Unchanged”.  
5. LAMA: Those subjects who left the therapy 
before advised duration or who did not follow the 
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instructions will be considered as Left against 
Medical Advice (LAMA). 
Statistical Analysis 
 All data generated and collected during the 
study was subjected to statistical analysis to reach to 
final results and conclusions. 
Statistical parameters like Paired t test, Graphical 
representations and statistical methods were applied 
to the data generated wherever possible, to find out 
the significance of improvement. Objective 
parameters (Quantitative data) parametric test are 
applied. 
Table 1: Showing Statistical Analysis 
Symptoms  P value Significance 
Severity of pain  <0.0001 Significant 
Duration of pain <0.0001 Significant 
Artava Pramana 0.0117 Significant 
Rajstrava avadhi 0.0117 Significant 
Nausea <0.0001 Significant 
Vomiting 0.0002 Significant 
Diarrhoea 0.0117 Significant 
Constipation 0.0008 Significant 
Faint 0.0059 Significant 
Giddiness 0.0014 Significant 
Effect of Matra Basti 
Table 2: Severity of Pain Wise Distribution 
Subject with Severity of Pain wise Symptom Subject without 
Severity of Pain 
wise Symptom 
 
BT 
AT 
Present Improved Absent 
No. of subject % No. of subject % No. of subject % No. of subject % No. of subject % 
30 100 0 0 23 76.66 7 23.33 0 0 
Out of 30 Subjects included in the trial, 30 subjects (100.00%) had symptom of severity of pain and none 
of the subject was without symptom. After Matrabasti, 23 subjects (76.66%) had improvement in severity of 
pain and 7 subjects (23.33) cured i.e. absent. 
Table 3: Duration of Pain Wise Distribution 
Subject with Duration of Pain wise Symptom Subject without 
Duration of Pain 
wise Symptom 
 
 BT 
AT 
Present Improved Absent 
No. of subject % No. of subject % No. of subject % No. of subject % No. of subject % 
30 100 1 3.33 22 73.33 7 23.33 0 0 
Out of 30 Subjects included in the trial, 30 subjects (100.00%) had symptom in Duration of Pain and 
none of the subject was without symptom. After Matrabasti, 22 subjects (73.33%) had improvement in 
Duration of pain and in 7 subjects (23.33%) it is cured i.e. absent and in 1 subject (3.33%) it was present. 
Table 4: Artava Pramana Wise Distribution 
Subject with Artava Pramana wise Symptom Subject without 
Artava Pramana wise 
Symptom 
 
BT 
AT 
Present Improved Absent 
No. of 
subject 
% No. of subject % No. of subject % No. of subject % No. of subject % 
13 43.33 7 23.33 5 16.66 1 3.33 17 56.66 
Out of 30 Subjects included in the trial, 13 subjects (43.33%) had symptom Artava Pramana and 17 
subjects (56.66%) were without symptom. After Matrabasti, 5 subjects (16.66%) had improvement in Artava 
Pramana and in 1 subject (3.33%) it is cured i.e. absent and in 7 subjects (23.33%) it was present.  
Table 5: Rajastrava Avadhi Wise Distribution 
Subject with Rajastrava Avadhi wise Symptom Subject without 
Rajastrava Avadhi 
wise Symptom 
 
BT 
AT 
Present Improved Absent 
No. of subject % No. of 
subject 
% No. of 
subject 
% No. of subject % No. of 
subject 
% 
13 43.33 7 23.33 5 16.66 1 3.33 17 56.66 
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Out of 30 Subjects included in the trial, 13 subjects (43.33%) had symptom Rajstrava Avadhi and 17 
subjects (56.66) were without symptom. After Matrabasti, 5 subjects (16.66%) had improvement in Rajstrava 
Avadhi and in 1 subject (3.33%) it is cured i.e. absent and in 7 subjects (23.33%) it was present. 
Table 6: Nausea Wise Distribution 
Subject with Nausea wise Symptom Subject without 
Nausea wise 
Symptom 
BT AT 
Present Improved Absent 
No. of subject % No. of subject % No. of subject % No. of subject % No. of subject % 
17 56.66 0 0 2 6.66 15 50.00 13 43.33 
Out of 30 Subjects included in the trial, 17 subjects (56.66%) had symptom Nausea and 13 subjects 
(43.33%) were without symptom. After Matrabasti, 2 subjects (6.66%) had improvement in Nausea and in 15 
subjects (50.00%) it is cured i.e. absent and in none of the subject it was present. 
Table 7: Vomiting Wise Distribution 
Subject with Vomiting wise Symptom Subject without 
Vomiting wise 
Symptom 
 
BT 
AT 
Present Improved Absent 
No. of subject % No. of 
subject 
% No. of subject % No. of subject % No. of subject % 
13 43.33 0 0 1 3.33 12 40.00 17 56.66 
Out of 30 Subjects included in the trial, 13 subjects (43.33%) had symptom Vomiting and 17 subjects 
(56.66) were without symptom. After Matrabasti, 1 subject (3.33%) had improvement in Vomiting and in 12 
subjects (40.00%) it is cured i.e. absent and in none of subject it was present. 
Table 8: Diarrhoea Wise Distribution 
Subject with Diarrhoea wise Symptom Subject without 
Diarrhoea wise 
Symptom 
 
BT 
AT 
Present Improved Absent 
No. of 
subject 
% No. of 
subject 
% No. of 
subject 
% No. of subject % No. of subject % 
6 20.00 0 0 0 0 6 20.00 24 80.00 
Out of 30 Subjects included in the trial, 6 subjects (20.00%) had symptom Diarrhoea and 24 subjects 
(80.00%) were without symptom. After Matrabasti, none of the subject had improvement in Diarrhoea and in 6 
subjects (20.00%) it is cured i.e. absent and in none of subject it was present. 
Table 9: Constipation Wise Distribution 
Subject with Constipation wise Symptom Subject without 
Constipation wise 
Symptom 
 
BT 
AT 
Present Improved Absent 
No. of 
subject 
% No. of subject % No. of 
subject 
% No. of 
subject 
% No. of 
subject 
% 
6 20.00 0 0 0 0 6 20.00 24 80.00 
Out of 30 Subjects included in the trial, 6 subjects (20.00%) had symptom Constipation and 24 subjects 
(80.00%) were without symptom. After Matrabasti, none of the subject had improvement in Constipation and 
in 6 subjects (20.00%) it is cured i.e. absent and in none of subject it was present. 
Table 10: Faint Wise Distribution 
Subject with Faint wise Symptom Subject without Faint 
wise Symptom  
BT 
AT 
Present Improved Absent 
No. of subject % No. of subject % No. of 
subject 
% No. of 
subject 
% No. of subject % 
7 23.33 0 0 0 0 7 23.33 23 76.66 
Out of 30 Subjects included in the trial, 7 subjects (23.33%) had symptom Faint and 23 subjects 
(76.66%) were without symptom. After Matrabasti, none of the subject had improvement in Faint and in 7 
subjects (23.33%) it is cured i.e. absent and in none of subject it was present. 
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Table 11: Giddiness Wise Distribution 
Subject with Giddiness wise Symptom Subject without 
Giddiness wise 
Symptom 
 
BT 
AT 
Present Improved Absent 
No. of 
subject 
% No. of 
subject 
% No. of 
subject 
% No. of 
subject 
% No. of 
subject 
% 
9 30.00 0 0 0 0 9 30.00 21 70.00 
Out of 30 Subjects included in the trial, 9 subjects (30.00%) had symptom Giddiness and 21 subjects 
(70.00%) were without symptom. After Matrabasti, none of the subject had improvement in Giddiness and in 9 
subjects (30.00%) it is cured i.e. absent and in none of subject it was present. 
Table 12: Showing Percentage of Relief 
Sr. No. Reg. No. Total Symptom Score 
Total Relief Score 
Relief 
% 
  
BT AT 
1 57502 12 8 4 33.33 
2 56751 5 2 3 60 
3 50523 11 6 5 45.45 
4 49809 12 6 6 50 
5 49544 6 2 4 66.66 
6 52177 13 4 9 69.23 
7 50043 8 2 6 75 
8 52968 11 2 9 81.81 
9 60003 12 2 10 83.33 
10 60475 6 2 4 66.66 
11 56231 11 2 9 81.81 
12 59802 13 6 7 53.84 
13 63337 7 2 5 71.42 
14 62176 11 2 9 81.81 
15 62170 9 2 7 77.77 
16 62175 9 2 7 77.77 
17 62338 14 4 10 71.42 
18 59376 4 0 4 100 
19 58482 10 2 8 80 
20 59748 5 3 2 40 
21 64611 10 5 5 50 
22 70196 7 2 5 71.42 
23 73197 10 4 6 60 
24 73183 8 4 4 50 
25 73254 9 3 6 66.66 
26 73247 12 6 6 50 
27 73262 7 2 5 71.42 
28 73277 8 3 5 62.5 
29 73538 11 5 6 54.54 
30 73525 4 0 4 100 
Clinical efficacy of the therapy under study 
Table showing statistical analysis 
Table 13: Showing Statistical analysis on Severity of pain 
Severity of Pain Mean Mean Difference SD  SEM Paired t value P value 
Initial 2.400      
1st cycle 1.400 1.000 0.371 0.067 14.75 <0.0001 
2nd cycle 1.067 1.333 0.547 0.099 13.36 <0.0001 
3rd cycle 1.000 1.400 0.563 0.102 13.61 <0.0001 
The table shows the statistical analysis for Severity of Pain where t-score shows the difference is 
significant at every follow ups. It means that the said therapy used for Pain of Kashtartava (Primary 
Dysmenorrhoea) subjects is effective. 
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Table 14: Showing Statistical analysis on Duration of Pain 
Duration of Pain Mean Mean Difference SD SEM Paired t value P value 
Initial 2.333      
1st cycle 1.567 0.767 0.679 0.124 6.185 <0.0001 
2nd cycle 1.033 1.300 0.651 0.118 10.93 <0.0001 
3rd cycle 1.000 1.333 0.660 0.120 11.05 <0.0001 
The table shows the statistical analysis for Duration of Pain where t-score shows the difference is 
significant at every follow ups. It means that the said therapy used for Duration of Pain in Kashtartava subjects 
is effective.  
Table 15: Showing Statistical analysis on Artava Pramana 
Artava Pramana Mean Mean Difference SD SEM Paired t value P value 
Initial 0.600      
1st cycle 0.500 0.100 0.305 0.055 1.795 0.0831 
2nd cycle 0.400 0.200 0.407 0.074 2.693 0.0117 
3rd cycle 0.400 0.200 0.407 0.074 2.693 0.0117 
The table shows the statistical analysis for Artava Pramana where t-score shows the difference is 
significant at 2nd and 3rd follow ups. It means that the said therapy used for Artava Pramana in Kashtartava 
subjects is effective.  
Table 16: Showing Statistical analysis on Rajastrava Avadhi 
Rajstrava Avadhi Mean Mean Difference SD SEM Paired t value P value 
Initial 0.600      
1st cycle 0.500 0.100 0.305 0.055 1.795 0.0831 
2nd cycle 0.400 0.200 0.407 0.074 2.693 0.0117 
3rd cycle 0.400 0.200 0.407 0.074 2.693 0.0117 
The table shows the statistical analysis for Rajastrava Avadhi where t-score shows the difference is 
significant at 2nd and 3rd follow ups. It means that the said therapy used for Rajastrava Avadhi in Kashtartava 
subjects is effective. 
Table 17: Showing Statistical analysis on Nausea 
Nausea Mean Mean Difference SD SEM Paired t value P value 
Initial 0.900      
1st cycle 0.267 0.633 0.615 0.112 5.641 <0.0001 
2nd cycle 0.100 0.800 0.805 0.147 5.442 <0.0001 
3rd cycle 0.067 0.833 0.834 0.152 5.473 <0.0001 
The table shows the statistical analysis for Nausea where t-score shows the difference is significant at 
every follow ups. It means that the said therapy used for Nausea in Kashtartava subject is effective.  
Table 18: Showing Statistical analysis on Vomiting 
Vomiting Mean Mean Difference SD  SEM Paired t value P value 
Initial 0.633      
1st cycle 0.200 0.433 0.504 0.092 4.709 <0.0001 
2nd cycle 0.067 0.567 0.728 0.132 4.264 0.0002 
3rd cycle 0.033 0.600 0.770 0.140 4.267 0.0002 
The table shows the statistical analysis for Vomiting where t-score shows the difference is significant at 
every follow ups. It means that the said therapy used for Vomiting in Kashtartava subjects is effective. 
Table 19: Showing Statistical analysis on Diarrhoea 
Diarrhoea Mean Mean Difference SD  SEM Paired t value P value 
Initial 0.400      
1st cycle 0.100 0.300 0.651 0.118 2.523 0.0174 
2nd cycle 0.000 0.400 0.814 0.148 2.693 0.0117 
3rd cycle 0.000 0.400 0.814 0.148 2.693 0.0117 
The table shows the statistical analysis for Diarrhoea where t-score shows the difference is significant 
at every follow ups. It means that the said therapy used for Diarrhoea in Kashtartava subjects is effective.  
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Table 20: Showing Statistical analysis on Constipation 
Constipation Mean Mean Difference SD  SEM Paired t value P value 
Initial 0.767      
1st cycle 0.367 0.400 0.621 0.113 3.525 0.0014 
2nd cycle 0.200 0.567 0.774 0.141 4.011 0.0004 
3rd cycle 0.267 0.500 0.731 0.133 3.746 0.0008 
The table shows the statistical analysis for Constipation where t-score shows the difference is 
significant at every follow ups. It means that the said therapy used for Constipation in Kashtartava subjects is 
effective.  
Table 21: Showing Statistical analysis on Faint 
Faint Mean Mean Difference SD  SEM Paired t value P value 
Initial 0.233      
1st cycle 0.000 0.233 0.430 0.078 2.971 0.0059 
2nd cycle 0.000 0.233 0.430 0.078 2.971 0.0059 
3rd cycle 0.000 0.233 0.430 0.078 2.971 0.0059 
 The table shows the statistical analysis for Faint where t-score shows the difference is significant at every 
follow ups. It means that the said therapy used for Faint in Kashtartava subjects is effective.  
Table 22: Showing Statistical analysis on Giddiness 
Giddiness Mean Mean Difference SD  SEM Paired t value P value 
Initial 0.300      
1st cycle 0.000 0.300 0.466 0.085 3.525 0.0014 
2nd cycle 0.000 0.300 0.466 0.085 3.525 0.0014 
3rd cycle 0.000 0.300 0.466 0.085 3.525 0.0014 
The table shows the statistical analysis for Giddiness where t-score shows the difference is significant at 
every follow ups. It means that the said therapy used for Giddiness in Kashtartava (Primary Dysmenorrhoea) 
subject is effective.  
DISCUSSION 
The observations noted in 30 subjects and 
displayed in tables, graphs and supplementary notes 
are critically discussed hereafter. 
It is observed that there was significant 
improvement in symptoms like Severity pain, 
Duration of pain and associated symptoms like 
Artava pramana, Rajstrav Avadhi, Nausea, Vomiting, 
Constipation, Diarrhoea, Faint and Giddiness.  
While treating any disease the Mula sthana of 
vitiated Dosha has to be treated first. According to 
Acharya Vagbhata, Guda is mula sthana of Apana vayu 
and Shroni, Basti, Medhra, Uru are the Sanchari 
sthana of Apana vata. Basti is said to be Pradhan 
chikitsa of Vata dosha. Therefore it can be concluded 
that due to Basti chikitsa vitiated Vata dosha gets 
mitigated and hence all the symptoms diminish. From 
the above study it has been observed that Til taila 
Matra Basti is very effective in subjects of 
Kashtartava. 
In this study, Basti is given only for 9 days for 
two cycles. Majority of subjects had history of 
Kashtartava for more than 3 years. If this Basti is 
given for a longer duration along with other 
medications results would be more significant. 
CONCLUSION 
Out of 30 subjects of Kashtartava in whom 
Matrabasti was administered, 2 subjects showed total 
relief in all symptoms (Cured), 21 subjects showed 
50% or more average improvement in all symptoms 
(Markedly improved), 7 subjects showed 
improvement ranging in between 25% to 50% 
(Improved) and none of the subject remain 
unchanged i.e. those subjects presenting less than 
25% improvement. 
No adverse effects of Matrabasti were 
observed in the clinical study. Therefore it can be 
concluded that due to Basti chikitsa vitiated Vata 
dosha gets mitigated and hence all the symptoms 
diminish. From the above study it has been observed 
that Til taila Matra Basti is very effective in subjects 
of Kashtartava. 
In future, further clinical studies are needed 
to be performed on a large sample size to backup the 
above findings. It was an effort to explore the treatise 
of Ayurveda to find an effective and easily 
approachable solution on the crisis. The treatise of 
Ayurveda has been partially explored in the form of 
Matrabasti on Kashtartava. 
REFERENCES 
1. Vd. Yadavji Trikamji Aacharya, Charak samhita, 
Ayurved Dipika commentary by Chakradutta, 
Varanasi, Chaukhambha Surbharati prakashana, 
Varanasi, 20058.p. 635-637, 681, 701 
Int. J. Ayur. Pharma Research, 2018;6(5):25-32 
     IJAPR | May 2018 | Vol 6 | Issue 5  32 
2. Vd. Yadavji Trikamji Aacharya, Sushruta samhita 
with Nibandhsangraha commentary by Dalhan, 
Varanasi, Chawkhamba Surbharati prakashana, 
Varanasi, 2003. p.261, 347, 536. 
3. Prof. A.D.Aathavale, Ashtangasangranha by 
Vruddha Vagbatta with commentary of Indu, 
Nagpur, Published by M. A. Aathavale, 1980. p. 
168-169.  
4. Anna Moreshwar Kunte and Krushna 
Ramachandra Shastri Navre, Ashtangahridaya 
with Sarvangsundar commentary by Arundatta 
and Ayurvedrasayan commentary by Hemadri, 
Varanasi, Chawkhamba Surbharati prakashana, 
2002.p. 193. 
5. S.G.Vartak, Doshdhatumalavidnyan, Worli, 
Mumbai, Ayurved Anusandhan, 1962. p.60-62 
6. Vd. Ranjitray Desai, Ayurvediya Kriyasharir, 8th 
edition, Allahabad, Shri Vaidyanath Ayurved 
Bhavan Ltd, 1999.p.766. 
7. Dr.Nandini Dhargalkar, Sharirkriya vidnyan, 
volume 1, 1st edition, Chaukhambha Sanskrit 
series, Varanasi, 2006.p.117-136. 
8. Vd.Hariprasad Kasture, Ayurvediya 
Panchakarma Vidnyana, Allahabad, Baidyanath 
Ayurveda Bhavana, 1999.p.396-397. 
9. Vd Nirmala Joshi, Ayurvedic concepts of 
Gynaecology, Sadashiv Peth Pune, Choukhamba 
Sanskrit Pratishthan, Delhi 1999,. 23-32. 
10. V.G. Pandubidri and Shirish N. Daftary, Shaw’s 
Textbook of Gynecology, 13th Edition, New Delhi, 
Elsevier, p. 314-319. 
11. Guyton and Hall, Textbook of medical 
physiology, Volume 2, 11th edition, Printed in 
Asia 2006.p. 1112-1117. 
12. C.C.Chatarjee, Human physiology volume 1 and 
2, 11th edition, Calcutta, 1992.p.4260-4265. 
 
 
 
 
 
 
 
Disclaimer: IJAPR is solely owned by Mahadev Publications - dedicated to publish quality research, while every effort has been taken to 
verify the accuracy of the content published in our Journal. IJAPR cannot accept any responsibility or liability for the articles content 
which are published. The views expressed in articles by our contributing authors are not necessarily those of IJAPR editor or editorial 
board members.  
Cite this article as:  
Jyoti Jangale. Efficacy of Matrabasti on Kashtartava (Primary 
Dysmenorrhoea). International Journal of Ayurveda and Pharma 
Research. 2018;6(5):25-32. 
Source of support: Nil, Conflict of interest: None Declared 
 
*Address for correspondence 
Dr Jyoti Jangale 
Assistant Professor,  
Dept. of Kriya Sharir,  
YMT Ayurvedic Medical College and 
Hospital, Kharghar, Navi Mumbai, 
Raigad, Maharashtra, India. 
Email: dr.jyotijangale@gmail.com 
Contact Number: 9819718214 
